StockHealthcare · Biotechnology

$VCNX

VACCINEX, INC.

Price · $VCNXvia TradingView

AI sentiment · 7d0 articles

No enriched coverage for $VCNX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $VCNX in the last 30 days.

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - Vaccinex ( OTC:VCNX )

ROCHESTER, N.Y., May 27, 2025 ( GLOBE NEWSWIRE ) -- Vaccinex, Inc.

APR 21·Benzinga

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research ( AACR ) - Vaccinex ( OTC:VCNX )

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma.

APR 21·GlobeNewswire

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research ( AACR )

Unique mechanism of pepinemab induced abundant, mature TLS, correlating with durable clinical benefit in HNSCC and in neoadjuvant study in melanoma.

via TradingView

News on $VCNX

All news →